USFDA nod to Shilpa Medicare for multiple sclerosis drug
Dimethyl Fumarate delayed release capsules is a generic of Tecfidera, it added.
- Country:
- India
Shilpa Medicare Thursday said it has received tentative approval from the US health regulator for Dimethyl Fumarate delayed release capsules, used for the treatment of relapsing forms of multiple sclerosis.
The company's abbreviated new drug application (ANDA) for Dimethyl Fumarate delayed release capsules in the strengths of 120 mg and 240 mg has been granted tentative approval by the United States Food and Drug Administration (USFDA), Shilpa Medicare said in a BSE filing.
Dimethyl Fumarate delayed release capsules is a generic of Tecfidera, it added.
Quoting IQVIA MAT second quarter 2018 data, Shilpa Medicare said the US market for Dimethyl Fumarate delayed release capsules is approximately USD 3.46 billion.
Shares of Shilpa Medicare were trading 3.92 per cent up at Rs 388.65 apiece on BSE.
(With inputs from agencies.)
- READ MORE ON:
- Food
- Food security
- Fast food
- Drug
- Pharmaceutical drug
- Multiple sclerosis
- Oral administration
- Route of administration
- Drug Enforcement Administration
- tentative USFDA nod
- United States Food
- multiple sclerosis drug
- tentative approval
- US health regulator
- Drug Administration
- Shares of Shilpa Medicare
- company's abbreviated new drug application
- PTI News
- Business News
- treatment of relapsing forms of multiple sclerosis
Google News